A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kim, Hyojin ^a,b   Jang, Se Jin ^c   Chung, Doo Hyun ^b   Yoo, Seol Bong ^d   Sun, Pingli ^b   Jin, Yan ^a,b   Nam, Kyung Han ^a,b   Paik, Jin Ho ^a,b   Chung, Jin Haeng ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Presbyterian Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN P40; PROTEIN P63; UVOMORULIN; VIMENTIN; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MOLECULAR MECHANICS; MORPHOMETRICS; MULTIVARIATE ANALYSIS; ONCOGENE; TUMOR BIOPSY; ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; PHENOTYPE; PROTO ONCOGENE; RISK; SOUTH KOREA; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENES, ERBB-1; GENES, RAS; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; ODDS RATIO; PHENOTYPE; RECEPTOR PROTEIN-TYROSINE KINASES; REPUBLIC OF KOREA;

EID: 84885996181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076999     Document Type: Article

References (33)

1. Devesa SS, Bray F, Vizcaino AP, Parkin DM, (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299.
2. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
3. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
4. Hsieh RK, Lim KH, Kuo HT, Tzen CY, Huang MJ, (2005) Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128: 317-321.
5. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, et al. (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32: 810-827.
6. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, et al. (2009) Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 63: 235-240.
7. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, et al. (2012) High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7: 323-330.
8. Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL (2013) KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol doi: 10.1038/modpathol.2013.74.
9. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, et al. (2007) Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 9: 320-326.
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
11. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012.
12. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223.
13. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515.
14. Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, et al. (2011) Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72: 309-315.
15. Popat S, Gonzalez D, Min T, Swansbury J, Dainton M, et al. (2012) ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer 75: 300-305.
16. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, et al. (2012) Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 25: 1462-1472.
17. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
18. Sobin LH GM WC (2009) TNM Classification of Malignant Tumours Seventh edition.
19. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234.
20. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization. J Thorac Oncol 6: 466-472.
21. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, et al. (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6: 1359-1366.
22. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253.
23. Chung JH, Choe G, Jheon S, Sung SW, Kim TJ, et al. (2009) Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 4: 1490-1495.
24. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, et al. (2004) Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 44: 147-155.
25. Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, et al. (2013) DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol 21: 229-239.
26. Kim H, Yoo SB, Sun P, Jin Y, Jheon S, et al. (2013) Alteration of the E-Cadherin/beta-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma. Korean J Pathol 47: 44-51.
27. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, et al. (2012) p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25: 405-415.
28. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL, (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24: 1348-1359.
29. Bilal H, Handra-Luca A, Bertrand JC, Fouret PJ, (2003) P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. J Histochem Cytochem 51: 133-139.
30. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, et al. (2002) P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33: 921-926.
31. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, et al. (2002) p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 198: 100-109.
32. Nonaka D, (2012) A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 36: 895-899.
33. Sakai Y, Nakai T, Ohbayashi C, Imagawa N, Yanagita E, et al. (2013) Immunohistochemical Profiling of ALK Fusion Gene-Positive Adenocarcinomas of the Lung. Int J Surg Pathol DOI: 10.1177/1066896913489345.